N
Neurogene Inc. (NGNE)
NGM – Real vaqt narxi. Valyuta: USD
31.54
+0.65 (2.10%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
31.54
+0.65 (2.10%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Neurogene Inc., klinik bosqichdagi biotexnologiya kompaniyasi, noyob nevrologik kasalliklar uchun gen terapiyasini ishlab chiqadi. Kompaniyaning mahsulot nomzodlari orasida Rett sindromini davolash uchun 1/2-faza klinik sinovlarida bo'lgan va adenoviral virus 9 ga qadoqlangan NGN-401; hamda CLN5 Batten kasalligini davolash uchun 1/2-faza klinik sinovlarida bo'lgan an'anaviy gen terapiyasi nomzodi NGN-101 mavjud. Kompaniya Edinburg universiteti, Virovek, Inc., Sigma-Aldrich Co. LLC. va Leland Stanford Junior universiteti bilan litsenziyalash shartnomasiga ega. Kompaniya 2018-yilda tashkil etilgan va Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew E. Mulberg CPI, FAAP, M.D. | Senior VP of Regulatory Affairs, Quality Assurance & Quality Control |
| Dr. Julie Jordan M.D. | Chief Medical Officer |
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & CEO |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
| Mr. Arvind Sreedharan | Senior Vice President of Business Operations |
| Mr. Ricardo Jimenez | Senior Vice President of Technical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-12 | 10-Q | ngne-20260331.htm |
| 2026-04-20 | 8-K | ngne-20260420.htm |
| 2026-04-16 | DEFA14A | a2026defa14a_notice.htm |
| 2026-04-16 | ARS | ef20070648_ars.pdf |
| 2026-03-24 | S-8 | neurogene-sx8xmarch2026.htm |
| 2026-03-24 | 8-K | ngne-20260324.htm |
| 2026-02-26 | 8-K | ngne-20260226.htm |
| 2026-01-12 | 8-K | ngne-20250811_d2.htm |
| 2025-11-13 | 8-K | ngne-20251113.htm |
| 2025-11-12 | 8-K | ngne-20251112.htm |
| Ms. Christina Shafer | Chief Commercial Officer |
| Ms. Christine Mikail Cvijic J.D. | President, CFO & Director |
| Ms. Donna M. Cochener-Metcalfe J.D., L.L.M. | Senior VP, General Counsel & Corporate Secretary |